ReviewInternational ophthalmology2011
Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.
Piergiorgio Neri et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this paperpooled itcites it